Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Algorithms | 1 | 2020 | 7346 | 0.25 | Why? |
| Vitamin K 1 | 1 | 2021 | 26 | 0.24 | Why? |
| Vitamin K Deficiency | 1 | 2020 | 30 | 0.21 | Why? |
| Triage | 1 | 2020 | 7151 | 0.21 | Why? |
| Prescription Drug Overuse | 1 | 2020 | 59 | 0.21 | Why? |
| Emergency Service, Hospital | 2 | 2020 | 14232 | 0.18 | Why? |
| Quinoxalines | 1 | 2019 | 95 | 0.18 | Why? |
| Vitamin K | 1 | 2020 | 263 | 0.18 | Why? |
| Benzofurans | 1 | 2019 | 91 | 0.17 | Why? |
| Netherlands | 6 | 2021 | 3533 | 0.16 | Why? |
| Pulmonary Aspergillosis | 1 | 2021 | 408 | 0.15 | Why? |
| Imidazoles | 1 | 2019 | 631 | 0.13 | Why? |
| Thorax | 1 | 2020 | 1873 | 0.10 | Why? |
| Ribavirin | 1 | 2017 | 1182 | 0.10 | Why? |
| Tomography, X-Ray Computed | 3 | 2020 | 25144 | 0.10 | Why? |
| Adaptive Immunity | 1 | 2021 | 2585 | 0.09 | Why? |
| Chloroquine | 2 | 2020 | 3152 | 0.09 | Why? |
| Hepatitis C, Chronic | 1 | 2017 | 973 | 0.09 | Why? |
| Thromboembolism | 1 | 2020 | 2101 | 0.08 | Why? |
| Hepatitis C | 1 | 2019 | 1514 | 0.08 | Why? |
| Bacterial Infections | 1 | 2020 | 2229 | 0.08 | Why? |
| Hydroxychloroquine | 2 | 2020 | 12447 | 0.08 | Why? |
| Sustained Virologic Response | 2 | 2019 | 378 | 0.08 | Why? |
| Artificial Intelligence | 1 | 2020 | 3543 | 0.07 | Why? |
| Fever | 1 | 2020 | 7795 | 0.06 | Why? |
| Immunity, Innate | 1 | 2021 | 6570 | 0.06 | Why? |
| Antiviral Agents | 3 | 2020 | 41703 | 0.06 | Why? |
| Lung | 2 | 2020 | 31049 | 0.06 | Why? |
| Biomarkers | 2 | 2021 | 23361 | 0.06 | Why? |
| Drug Administration Routes | 1 | 2020 | 106 | 0.05 | Why? |
| Extracellular Matrix Proteins | 1 | 2020 | 95 | 0.05 | Why? |
| Protein S | 1 | 2020 | 150 | 0.05 | Why? |
| Calcium-Binding Proteins | 1 | 2020 | 121 | 0.05 | Why? |
| Retrospective Studies | 5 | 2021 | 105322 | 0.05 | Why? |
| Hepacivirus | 2 | 2019 | 1509 | 0.05 | Why? |
| Anti-Bacterial Agents | 1 | 2020 | 10083 | 0.05 | Why? |
| Thrombosis | 1 | 2020 | 7504 | 0.04 | Why? |
| Aged | 8 | 2021 | 215776 | 0.04 | Why? |
| Blood Culture | 1 | 2020 | 308 | 0.04 | Why? |
| Middle Aged | 9 | 2021 | 270681 | 0.04 | Why? |
| Hospital Mortality | 1 | 2021 | 22087 | 0.04 | Why? |
| Cyclopropanes | 1 | 2019 | 332 | 0.04 | Why? |
| Male | 10 | 2021 | 367725 | 0.04 | Why? |
| Genotype | 2 | 2019 | 4697 | 0.04 | Why? |
| Female | 10 | 2021 | 380317 | 0.04 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.04 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.04 | Why? |
| Severity of Illness Index | 2 | 2021 | 48226 | 0.04 | Why? |
| Risk Factors | 2 | 2021 | 71621 | 0.04 | Why? |
| Humans | 14 | 2021 | 930598 | 0.04 | Why? |
| Carbamates | 1 | 2019 | 485 | 0.04 | Why? |
| Drug Therapy, Combination | 2 | 2019 | 7268 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2020 | 2324 | 0.03 | Why? |
| Aged, 80 and over | 2 | 2020 | 88759 | 0.03 | Why? |
| Cohort Studies | 3 | 2021 | 36005 | 0.03 | Why? |
| L-Lactate Dehydrogenase | 1 | 2021 | 1995 | 0.03 | Why? |
| Sofosbuvir | 1 | 2017 | 518 | 0.03 | Why? |
| Treatment Failure | 1 | 2019 | 2106 | 0.03 | Why? |
| Propensity Score | 1 | 2021 | 2690 | 0.03 | Why? |
| Belgium | 1 | 2019 | 2064 | 0.03 | Why? |
| Antimicrobial Stewardship | 1 | 2020 | 931 | 0.03 | Why? |
| Pneumonia, Viral | 1 | 2020 | 243684 | 0.03 | Why? |
| Administration, Oral | 1 | 2019 | 2340 | 0.03 | Why? |
| Coronavirus Infections | 1 | 2020 | 253789 | 0.03 | Why? |
| Leukocytes, Mononuclear | 1 | 2021 | 2115 | 0.03 | Why? |
| Sexually Transmitted Diseases | 1 | 2019 | 694 | 0.03 | Why? |
| Prospective Studies | 3 | 2021 | 43301 | 0.03 | Why? |
| Sulfonamides | 1 | 2019 | 1294 | 0.03 | Why? |
| Adult | 4 | 2020 | 244371 | 0.02 | Why? |
| Intensive Care Units | 3 | 2021 | 29594 | 0.02 | Why? |
| Anticoagulants | 2 | 2021 | 9563 | 0.02 | Why? |
| Adolescent | 1 | 2020 | 86841 | 0.02 | Why? |
| Young Adult | 1 | 2020 | 93724 | 0.02 | Why? |
| Lymphopenia | 1 | 2021 | 2669 | 0.02 | Why? |
| Diabetes Complications | 1 | 2021 | 2358 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2021 | 6543 | 0.02 | Why? |
| Body Mass Index | 1 | 2021 | 4306 | 0.02 | Why? |
| Incidence | 2 | 2020 | 25622 | 0.02 | Why? |
| Guideline Adherence | 1 | 2020 | 2309 | 0.02 | Why? |
| Amides | 1 | 2019 | 1864 | 0.02 | Why? |
| Survival Analysis | 1 | 2021 | 7592 | 0.02 | Why? |
| Acute Disease | 1 | 2019 | 6029 | 0.02 | Why? |
| Polymerase Chain Reaction | 1 | 2021 | 6740 | 0.02 | Why? |
| Liver Cirrhosis | 1 | 2017 | 1810 | 0.02 | Why? |
| Immunocompromised Host | 1 | 2021 | 5150 | 0.02 | Why? |
| Research Design | 1 | 2020 | 5830 | 0.02 | Why? |
| Patient Admission | 1 | 2020 | 5250 | 0.02 | Why? |
| Length of Stay | 1 | 2021 | 11042 | 0.02 | Why? |
| Treatment Outcome | 2 | 2020 | 51732 | 0.02 | Why? |
| Pandemics | 2 | 2020 | 389249 | 0.01 | Why? |
| Coinfection | 1 | 2020 | 6820 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2020 | 22971 | 0.01 | Why? |
| Respiratory Insufficiency | 1 | 2021 | 7301 | 0.01 | Why? |
| Hospitalization | 2 | 2020 | 54280 | 0.01 | Why? |
| Cytokines | 1 | 2021 | 15010 | 0.01 | Why? |
| Inflammation | 1 | 2021 | 13255 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2021 | 22116 | 0.01 | Why? |
| Time Factors | 1 | 2019 | 31397 | 0.01 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.01 | Why? |
Dofferhoff's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(99)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(158)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_